Increased levels of CSF phosphorylated tau in apolipoprotein E ɛ4 carriers with mild cognitive impairment
- 31 December 2005
- journal article
- research article
- Published by Elsevier BV in Neuroscience Letters
- Vol. 391 (1-2), 48-50
- https://doi.org/10.1016/j.neulet.2005.08.030
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairmentMolecular Psychiatry, 2003
- Biological markers for therapeutic trials in Alzheimer’s diseaseNeurobiology of Aging, 2003
- CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjectsNeurology, 2002
- Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's diseaseAnnals of Neurology, 2001
- Both total and phosphorylated tau are increased in Alzheimer's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231Annals of Neurology, 2001
- CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective StudyExperimental Neurology, 2000
- Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patientsNeuroscience Letters, 2000
- Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein ENew England Journal of Medicine, 1996
- Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individualsPublished by American Medical Association (AMA) ,1995